US 11,865,170 B2
DNA vaccine for human papillomavirus and method for using the same
Yung-Nien Chang, Elkridge, MD (US)
Assigned to Papivax Biotech Inc., Taipei (TW)
Filed by Papivax Biotech Inc., Taipei (TW)
Filed on Nov. 23, 2021, as Appl. No. 17/534,256.
Claims priority of provisional application 63/117,473, filed on Nov. 24, 2020.
Prior Publication US 2022/0160865 A1, May 26, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 35/76 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 35/76 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/585 (2013.01)] 10 Claims
 
1. A DNA vaccine, comprising:
a DNA construct comprising a fusion gene,
wherein the fusion gene includes an optimized human papillomavirus (HPV) subsequence encoding at least one HPV antigen, and
wherein the optimized HPV subsequence comprises one or more of:
an HPV-16 E6 expressing gene set forth in SEQ ID NO: 1,
an HPV-16 E7 expressing gene set forth in SEQ ID NO: 2,
an HPV-18 E6 expressing gene set forth in SEQ ID NO: 3, and
an HPV-18 E7 expressing gene set forth in SEQ ID NO: 4.